Development of the first low nanomolar Liver Receptor Homolog-1 agonist through structure-guided design
S. G. Mays, A. R. Flynn, J. L. Corneilson, C. D. Okafor, H. Wang, G. Wang, X. Huang, H. N. Donaldson, E. J. Millings, R. Polavarapu, D. Moore, J. Calvert, N. Jui, E. A. Ortlund
This study develops the first low nanomolar LRH-1 agonist using structure-guided design, showing increased potency and anti-inflammatory effects in an organoid model.
bioRxiv · May 17, 2019Pharmacology & Toxicology